Fig. 2
From: Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer
The performance of the TRY-RNA signature in the validation cohort. a Expression heatmap of the sncRNA species within the TRY-RNA signature in the validation cohort. b Principal component analysis of the TRY-RNA signature. PC1: the first principal component; PC2: the second principal component. PC1 significantly differed between the controls and lung cancer patients (t-test: P = 3.1 × 10− 3), between the controls and TB patients (t-test: P = 4.7 × 10− 6), and between the lung cancer and TB patients (t-test: P = 4.1 × 10− 8). c Comparison of the TRY-RNA index among the control, lung cancer, and TB subjects in the validation cohort. d The ROC curve of the TRY-RNA index in distinguishing between lung cancer and non-cancer subjects and between TB and non-TB subjects in the validation cohort